AKTX · Akari Therapeutics Plc
The AI's read
Akari says AKTX-101 produced meaningful anti-tumor activity in preclinical urothelial models, outperforming Padcev in one metastatic model and slowing Trodelvy-resistant tumors. The payload is a novel PH1 RNA-spliceosome modulator, so the biology looks differentiated versus Top1 and microtubule ADCs. The market barely reacted and AKTX is trading near the low end with RSI 17, implying expectations are low. The company targets a Phase 1 by mid-2027, so upside is binary and long dated with execution and cash risk. We lean bullish because the data show mechanistic differentiation and there is an IND path on the calendar. Conviction 84%: meaningful upside if human data translate, but high clinical and timing risk means smaller position sizing is prudent.